Naeger LK - Search Results

1

Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.

White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK. White KL, et al. Among authors: naeger lk. Antimicrob Agents Chemother. 2002 Nov;46(11):3437-46. doi: 10.1128/AAC.46.11.3437-3446.2002. Antimicrob Agents Chemother. 2002. PMID: 12384348 Free PMC article.

2

ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase.

Naeger LK, Margot NA, Miller MD. Naeger LK, et al. Antimicrob Agents Chemother. 2002 Jul;46(7):2179-84. doi: 10.1128/AAC.46.7.2179-2184.2002. Antimicrob Agents Chemother. 2002. PMID: 12069972 Free PMC article.

3

Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.

White KL, Chen JM, Margot NA, Wrin T, Petropoulos CJ, Naeger LK, Swaminathan S, Miller MD. White KL, et al. Among authors: naeger lk. Antimicrob Agents Chemother. 2004 Mar;48(3):992-1003. doi: 10.1128/AAC.48.3.992-1003.2004. Antimicrob Agents Chemother. 2004. PMID: 14982794 Free PMC article.

4

Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.

Naeger LK, Margot NA, Miller MD. Naeger LK, et al. Antivir Ther. 2001 Jun;6(2):115-26. Antivir Ther. 2001. PMID: 11491416

5

Tenofovir (PMPA) is less susceptible to pyrophosphorolysis and nucleotide-dependent chain-terminator removal than zidovudine or stavudine.

Naeger LK, Margot NA, Miller MD. Naeger LK, et al. Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):635-9. doi: 10.1081/NCN-100002340. Nucleosides Nucleotides Nucleic Acids. 2001. PMID: 11563081

6

Mechanisms of HIV-1 nucleoside reverse transcriptase inhibitor resistance: is it all figured out?

Naeger LK, Miller MD. Naeger LK, et al. Curr Opin Investig Drugs. 2001 Mar;2(3):335-9. Curr Opin Investig Drugs. 2001. PMID: 11575701 Review.

7

Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir.

Tuske S, Sarafianos SG, Clark AD Jr, Ding J, Naeger LK, White KL, Miller MD, Gibbs CS, Boyer PL, Clark P, Wang G, Gaffney BL, Jones RA, Jerina DM, Hughes SH, Arnold E. Tuske S, et al. Among authors: naeger lk. Nat Struct Mol Biol. 2004 May;11(5):469-74. doi: 10.1038/nsmb760. Epub 2004 Apr 25. Nat Struct Mol Biol. 2004. PMID: 15107837

8

Running a tightrope: regulatory challenges in the development of antiretrovirals.

Naeger LK, Struble KA, Murray JS, Birnkrant DB. Naeger LK, et al. Antiviral Res. 2010 Jan;85(1):232-40. doi: 10.1016/j.antiviral.2009.07.016. Epub 2009 Aug 7. Antiviral Res. 2010. PMID: 19665489 Review.

9

Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients.

Naeger LK, Harrington P, Komatsu T, Deming D. Naeger LK, et al. Antivir Ther. 2016;21(6):481-488. doi: 10.3851/IMP3033. Epub 2016 Feb 11. Antivir Ther. 2016. PMID: 26866979 Clinical Trial.

10

Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients.

Naeger LK, Struble KA. Naeger LK, et al. AIDS. 2007 Jan 11;21(2):179-85. doi: 10.1097/QAD.0b013e3280119213. AIDS. 2007. PMID: 17197808 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

36 results

Search Page